BR0203865A - Métodos relacionados com as repetições a-c da sequência z a montante do gene da aldose redutase - Google Patents

Métodos relacionados com as repetições a-c da sequência z a montante do gene da aldose redutase

Info

Publication number
BR0203865A
BR0203865A BR0203865-0A BR0203865A BR0203865A BR 0203865 A BR0203865 A BR 0203865A BR 0203865 A BR0203865 A BR 0203865A BR 0203865 A BR0203865 A BR 0203865A
Authority
BR
Brazil
Prior art keywords
upstream
aldose reductase
reductase gene
methods related
sequence repeats
Prior art date
Application number
BR0203865-0A
Other languages
English (en)
Inventor
David Albert Fryburg
Solomon Samuel Klioze
Patrice Marie Milos
Peter Joseph Oates
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0203865A publication Critical patent/BR0203865A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MéTODOS RELACIONADOS COM AS REPETIçõES A-C DA SEQuêNCIA Z A MONTANTE DO GENE DA ALDOSE REDUTASE". Esta invenção refere-se a métodos de caracterizar indivíduos e métodos de tratamento ou prevenção de doenças e condições patológicas relacionadas com a seq³ência polimórfica de repetições A-C aproximadamente localizada aproximadamente 2,1 kb a montante do gene da aldose redutase.
BR0203865-0A 2001-09-28 2002-09-24 Métodos relacionados com as repetições a-c da sequência z a montante do gene da aldose redutase BR0203865A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32592701P 2001-09-28 2001-09-28

Publications (1)

Publication Number Publication Date
BR0203865A true BR0203865A (pt) 2003-09-16

Family

ID=23270033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0203865-0A BR0203865A (pt) 2001-09-28 2002-09-24 Métodos relacionados com as repetições a-c da sequência z a montante do gene da aldose redutase

Country Status (6)

Country Link
US (1) US20030114357A1 (pt)
EP (1) EP1298223A3 (pt)
JP (1) JP2003180399A (pt)
BR (1) BR0203865A (pt)
CA (1) CA2404723A1 (pt)
MX (1) MXPA02009566A (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US8415364B2 (en) 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
DE69322882T2 (de) * 1992-10-26 1999-08-19 The Government Of The United States Of America As Intrazelluläre inhibitoren der aldose-reduktase
US6074822A (en) * 1995-11-03 2000-06-13 Board Of Trustees Operating Michigan State University Method for testing for risk of diabetes
CN101029338B (zh) * 2001-03-30 2010-05-19 香港中文大学 通过醛糖还原酶基因型确定白内障的风险率

Also Published As

Publication number Publication date
CA2404723A1 (en) 2003-03-28
EP1298223A3 (en) 2003-07-23
JP2003180399A (ja) 2003-07-02
EP1298223A2 (en) 2003-04-02
US20030114357A1 (en) 2003-06-19
MXPA02009566A (es) 2003-03-12

Similar Documents

Publication Publication Date Title
NO20034056D0 (no) Proliferative sykdommer
BR0310092A (pt) Combinação de compostos orgânicos
HK1112941A1 (en) Use of a33 antigens and jam-it a33
MXPA04000179A (es) Oligonucleotidos sinteticos de hebra doble para inhibicion especifica de expresion de gene.
NO20035025D0 (no) Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
MA31767B1 (fr) Composes organiques et leurs utilisations
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
DE60234269D1 (de) Substituierte aryl 1,4-pyrazin derivate
ZA200707021B (en) Use in therapy of a small molecule
HUP0402029A2 (hu) Peptidalapú multimer célzott kontrasztanyagok
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
WO2003013437A3 (en) Compositions and methods for the prevention and treatment of huntington's disease
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
TW200509892A (en) Novel aminobenzophenone compounds
BR0203865A (pt) Métodos relacionados com as repetições a-c da sequência z a montante do gene da aldose redutase
BR0211450A (pt) Método terapêutico
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
MA30485B1 (fr) Aminothiazoles et leurs utilisations
ZA200306124B (en) Method of treating of demyelinating diseases or conditions.
WO2006015191A3 (en) Multicyclic lonidamine analogs
SE0301854L (sv) Antiigensättningsbehandling
ITMI20031388A1 (it) Formulazioni per il trattamento e la prevenzione di patologie della prostata.
BRPI0415355A (pt) triarilimidazóis
ITTO20020284A0 (it) Procedimento per la sterilizzazione e la neutralizzazione di odori dell'aria.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010.